The corporate’s newly launched Wegovy weight reduction drugs have proven robust uptake within the US.
Months after implementing sweeping job cuts at its Monksland facility, Danish drug-maker Novo Nordisk has introduced a €432m funding on the Athlone-based plant to advance the its manufacturing capability for GLP-1 medicine.
In keeping with Novo, the funding goes towards upgrading and retrofitting the Athlone facility to enhance the manufacturing capability for its weight reduction tablets. The growth will enable Eire to function a essential hub for servicing markets exterior the US, it mentioned.
“With the funding within the Athlone facility, Novo Nordisk is increasing its manufacturing capacities for oral merchandise, which is able to allow us to fulfill each present and future international demand exterior the US,” mentioned Kasper Bodker Mejlvang, govt vice-president of chemistry, manufacturing and management, and product provide at Novo Nordisk.
The funding comes after Novo launched its fashionable weight reduction drug Wegovy in a capsule type in January. Early uptake of the capsule within the US was greater than twice that of any earlier weight reduction drug launch within the nation, the corporate’s US chief advised CNBC later that month.
CEO Mike Doustdar advised Bloomberg final month that greater than 240,000 Individuals are already taking Wegovy drugs. In the meantime, College School London estimated than round 1.6m adults within the UK used weight reduction medicine reminiscent of Wegovy and Mounjaro between early 2024 to early 2025.
The freshly introduced retrofitting and growth tasks in Athlone cowl 45 acres of land, and is about to create as much as building 600 jobs in response to the corporate. The tasks shall be finalised from the tip of 2027 by means of 2028.
The Danish pharmaceutical large employed round 400 on the Monksland, Athlone facility final September, previous to the necessary redundancy announcement. Stories on the time instructed that the positioning would lose round 115 jobs. Novo Nordisk’s newest numbers present that the ability now employs solely 260.
Globally, the corporate at the moment employs round 68,800 after reducing almost 10,000 roles since September. Novo Nordisk expects the job cuts to ship complete annualised financial savings of €1.07bn by 2026.
“As we speak’s funding announcement is a vote of confidence in Athlone, the Midlands and the expert workforce we’ve got labored arduous to develop. It’s going to assist drive innovation, create extremely expert jobs and additional strengthen Eire’s pharmaceutical ecosystem,” commented Minister for Enterprise, Tourism and Employment, Peter Burke TD.
“Eire hosts 9 of the highest 10 international pharma firms, producing a good portion of the world’s most progressive medicine, solidifying our nation’s function as a central hub for pharmaceutical manufacturing.”
IDA CEO Michael Lohan added: “Athlone continues to show its capability to draw giant scale, high-value manufacturing tasks, supported by a talented workforce and collaborative ecosystem. This growth reinforces Athlone as a significant contributor to Eire’s life sciences sector and our long-term regional growth ambitions.”
Don’t miss out on the information you’ll want to succeed. Join the Each day Transient, Silicon Republic’s digest of need-to-know sci-tech information.
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the most recent breakthroughs, get unique updates, and join with a world community of future-focused thinkers.
Unlock tomorrow’s tendencies as we speak: learn extra, subscribe to our e-newsletter, and turn out to be a part of the NextTech neighborhood at NextTech-news.com
